| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/PEDI.12280 |
| P698 | PubMed publication ID | 25940861 |
| P50 | author | William V Tamborlane | Q65054855 |
| Eda Cengiz | Q65054866 | ||
| Katrina Ruedy | Q65054902 | ||
| Craig Kollman | Q65054917 | ||
| Crystal O'Connor | Q84596679 | ||
| Roy W. Beck | Q88156417 | ||
| Desmond Schatz | Q88418652 | ||
| Brigid Gregg | Q89779781 | ||
| Peiyao Cheng | Q114455245 | ||
| Georgeanna J Klingensmith | Q114455253 | ||
| Pediatric Diabetes Consortium | Q114455255 | ||
| P2093 | author name string | Joyce M Lee | |
| P2860 | cites work | The potentially poor response to outpatient diabetes care in urban African-Americans | Q32049953 |
| Islet beta cell failure in type 2 diabetes | Q34698810 | ||
| The proinsulin C-peptide--a multirole model | Q35805808 | ||
| Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study | Q35822130 | ||
| Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes | Q35852840 | ||
| Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study | Q35968784 | ||
| Progressive deterioration of β-cell function in obese youth with type 2 diabetes | Q36828932 | ||
| Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. | Q36868320 | ||
| Continuous C-peptide loss in patients with type 1 diabetes and multiethnic background | Q45152230 | ||
| Types of pediatric diabetes mellitus defined by anti-islet autoimmunity and random C-peptide at diagnosis | Q46248035 | ||
| Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients | Q46909698 | ||
| C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. | Q47299422 | ||
| Glycemic control in youth with type 2 diabetes declines as early as two years after diagnosis. | Q51392366 | ||
| Type 2 diabetes-a matter of beta-cell life and death? | Q53873519 | ||
| P433 | issue | 4 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 274-280 | |
| P577 | publication date | 2015-05-05 | |
| P1433 | published in | Pediatric Diabetes | Q7159203 |
| P1476 | title | C-peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry | |
| P478 | volume | 17 |
| Q36608392 | Expanding Treatment Options for Youth With Type 2 Diabetes: Current Problems and Proposed Solutions: A White Paper From the NICHD Diabetes Working Group |
| Q47609030 | Initial Presentation of Type 2 Diabetes in Adolescents Predicts Durability of Successful Treatment with Metformin Monotherapy: Insights from the Pediatric Diabetes Consortium T2D Registry |
| Q48242614 | Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes |
| Q92544156 | Serum C-peptide and osteocalcin levels in children with recently diagnosed diabetes |
Search more.